Zobrazeno 1 - 10
of 627
pro vyhledávání: '"Yuqin Song"'
Autor:
Baopeng Ding, Haifei Hu, Yunpeng Cao, Ruirui Xu, Yujing Lin, Tahir ul Qamar Muhammad, Yuqin Song, Guangqi He, Youzhi Han, Huangping Guo, Jun Qiao, Jianguo Zhao, Xinxin Feng, Sheng Yang, Xuhu Guo, Rajeev Kumar Varshney, Liulin Li
Publikováno v:
Horticultural Plant Journal, Vol 10, Iss 6, Pp 1274-1290 (2024)
The pear (Pyrus spp.) is well known for diverse flavors, textures, and global horticultural importance. However, the genetic diversity responsible for its extensive phenotypic variations remains largely unexplored. Here, we de novo assembled and anno
Externí odkaz:
https://doaj.org/article/3205cad20e5b457bb53d30dc435ef752
Autor:
Hui Zhou, Jun Zhu, Yu Yang, Wei Yang, Liling Zhang, Lihong Liu, Mingzhi Zhang, Chuan He, Mei Zhang, Sujun Gao, Zhiming Li, Min Zhou, Hongmei Jing, Qingyuan Zhang, Ying Cheng, Yuqin Song, Zhengzi Qian, Xiuhua Sun, Wenyu Li, Haiyan Yang, Feng Yan, Ying Xiang, Bing Xu, Weihua Zhang, Xiaohong Zhang, Jie Jin, Huilan Liu, Weili Zhao, Ru Feng, Wenqi Jiang, Hong Cen, Fangfang Lv, Yunhong Huang, Ding Yu, Qunyi Guo, Lie Lin, Jianzhen Shen, Donghua Zhang, Jishi Wang, Xiongpeng Zhu, Meizuo Zhong, Jingbo Wang, Zhao Wang, Hongguo Zhao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background In patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL), a phase 3 trial was carried out to evaluate the efficacy and safety of zuberitamab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CH
Externí odkaz:
https://doaj.org/article/455cdb1f9ecd4902a56bf02e56ac8ada
Autor:
Chao Wang, Shiwei Wang, Shisong Jing, Yuan Zeng, Lili Yang, Yongqi Mu, Zixuan Ding, Yuqin Song, Yanmei Sun, Gang Zhang, Dawei Wei, Ming Li, Yingfei Ma, Haijian Zhou, Linhuan Wu, Jie Feng
Publikováno v:
Advanced Science, Vol 11, Iss 33, Pp n/a-n/a (2024)
Abstract Klebsiella pneumoniae, a major clinical pathogen known for causing severe infections, is attracting heightened attention due to its escalating antibiotic resistance. Phages are emerging as a promising alternative to antibiotics; however, the
Externí odkaz:
https://doaj.org/article/f7d272e4ccca439498b1227d3dd99130
Autor:
Ningjing Lin, Xiuhua Sun, Hui Zhou, Liqun Zou, Keshu Zhou, Lihong Liu, Haiyan Yang, Kai Hu, Qingqing Cai, Yao Liu, Jie Jin, Liling Zhang, Wenyu Li, Ye Guo, Wei Yang, Feng Luo, Zhenguang Wang, Rong Zhu, Lei Yang, Dan Song, Yuqin Song, Jun Zhu
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Loncastuximab tesirine (Lonca), an antibody conjugate targeting CD19, has demonstrated significant clinical benefit in R/R DLBCL in a global phase
Externí odkaz:
https://doaj.org/article/f8f59c1272c6425db6c5b7bf6bcbf17a
Publikováno v:
mLife, Vol 3, Iss 1, Pp 101-109 (2024)
Abstract Insertion sequences (ISs) promote the transmission of antimicrobial resistance genes (ARGs) across bacterial populations. However, their contributions and dynamics during the transmission of resistance remain unclear. In this study, we selec
Externí odkaz:
https://doaj.org/article/ca44ec73053e44268c5ab364d9750c2c
Autor:
Yanfei Liu, Lingyan Ping, Yuqin Song, Yongjing Tang, Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, Meng Wu, Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu, Yan Xie
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin
Externí odkaz:
https://doaj.org/article/fa08cf055ddf4c60af21f800463a0902
Autor:
Cen Lin, Xiaohong Ren, Mengqin Dai, Yuhang Wu, Lu Pan, Yuqin Song, Yu Cen, Qiuyue Fan, Cailin Xie, Jiarui Shao, Ying Chen, Yao Wang, Jiaming Luo
Publikováno v:
European Journal of Psychotraumatology, Vol 15, Iss 1 (2024)
Background: The western region of China has a dense population, relatively underdeveloped economy, and a significant number of left-behind children. Currently, the prevalence of adolescent psychological abuse, neglect, and the factors associated with
Externí odkaz:
https://doaj.org/article/15965b296852475686e2faf1a9b24483
Autor:
Jingcheng Chen, Jiangshuo Li, Jingxuan Wu, Yuqin Song, Lijun Li, Jianxiong Zhang, Ruihua Dong
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract A drug–drug interaction (DDI) trial of cytochrome P450 3A (CYP3A) is a necessary part of early‐phase trials of drugs mainly metabolized by this enzyme, but CYP3A DDI clinical trials do not have a standard design, especially for Chinese p
Externí odkaz:
https://doaj.org/article/5b34566ea10c4afbb64800e6ba5a36ae
Autor:
Yuqin Song, Shang-Ju Wu, Zhixiang Shen, Donglu Zhao, Thomas Sau Yan Chan, Huiqiang Huang, Lugui Qiu, Jianyong Li, Tran-der Tan, Jun Zhu, Yongping Song, Wei-Han Huang, Weili Zhao, Herman Sung Yu Liu, Wei Xu, Naizhi Chen, Jun Ma, Cheng-Shyong Chang, Eric Wai Choi Tse
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-26 (2023)
Abstract Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good cl
Externí odkaz:
https://doaj.org/article/910b3c2480ed4cd4b9096ea9dadac833
Autor:
Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang, Tycel J. Phillips, Stephen Opat, Cheng Fang, Shaohui Sun, Jun Zhu
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18643-18653 (2023)
Abstract Background We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second‐line versus later‐line. Here, we present
Externí odkaz:
https://doaj.org/article/1bc9e62404054e8489c6afc31806b1b4